A Randomized Placebo Controlled Study Of OSI-774 Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jul 2013 Last checked against National Cancer Institute of Canada record.
- 01 Jul 2011 Erlotinib was approved in Japan based on results from this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History